Exemestane for breast-cancer prevention in postmenopausal women.

Publication Type:

Journal Article

Authors:

Goss, Paul E; Ingle, James N; Alés-Martínez, José E; Cheung, Angela M; Chlebowski, Rowan T; Wactawski-Wende, Jean; McTiernan, Anne; Robbins, John; Johnson, Karen C; Martin, Lisa W; Winquist, Eric; Sarto, Gloria E; Garber, Judy E; Fabian, Carol J; Pujol, Pascal; Maunsell, Elizabeth; Farmer, Patricia; Gelmon, Karen A; Tu, Dongsheng; Richardson, Harriet

Source:

The New England journal of medicine, Volume 364, Issue 25, p.2381-91 (2011)

Keywords:

2011, Adult, Aged, Aged, 80 and over, Androstadienes, Aromatase Inhibitors, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Center-Authored Paper, Double-Blind Method, Female, Follow-Up Studies, Humans, Incidence, Middle Aged, Neoplasm Invasiveness, Postmenopause, Prevention Center Core Facility, Public Health Sciences Division, Quality of Life, Risk Factors, Shared Resources

Abstract:

Tamoxifen and raloxifene have limited patient acceptance for primary prevention of breast cancer. Aromatase inhibitors prevent more contralateral breast cancers and cause fewer side effects than tamoxifen in patients with early-stage breast cancer.